Pharmaceutical major Ranbaxy had got the US Food and Drug Administration (FDA) approval for exclusively selling the generic version of Aricept. Thus, CNBC-TV18 presumes that the company has either launched the Aricept generic or they are very close to launching it, reports Ekta Batra.
The approval has most likely been given via the site transfer of the OHM Labs. Ranbaxy has six-month exclusivity on the Aricept generic, which is Japanese drug maker Eisai's biggest selling drug in the US with a market of USD 2.4 billion there and USD 3 billion market globally. The drug is used in the treatment of Alzheimer's. With this, the pharma major expects to generate USD 200 million revenue and USD 110 million profit in the next six months. Ranbaxy, which may start selling the Aricept generic in the US after the patent on the medicine expires on November 25, also expects to add Rs 16 to its EPS. Aricept launch affirms that Ranbaxy might on track to launch the generic version of Lipitor in November 2011, on which it has exclusivity.
No comments:
Post a Comment